Business● Low5d ago · Oct 29, 2026, 6:00 PM
Alnylam anticipates $4.2B–$4.5B 2026 TTR sales, expands TRITON-CM to ~2,250 patients while keeping ~2030 launch timing
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Alnylam anticipates $4.2B–$4.5B in TTR sales by 2026 and plans to expand its TRITON-CM program to approximately 2,250 patients, while maintaining a launch timing around 2030. This details the company's future financial projections and clinical development plans.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business13m agoCommunity Healthcare declares $0.33 dividendSeeking Alpha TechBusiness16m agoBMW profits fall as carmaker warns of possible 2026 loss in car divisionEuroNews [en]Business16m agoBiggest stock movers Wednesday: Solar stocks, AMD, SMCI, and moreSeeking Alpha TechBusiness24m agoAutohome Non-GAAP EPADS of $0.36 beats by $0.06, revenue of $196.1M beats by $7.87MSeeking Alpha Tech